Give Feedback
Showing 133 results
  • Viewpoint

    June 25, 2025
    Life sciences enterprises operate in an increasingly complex engagement landscape due to rising content fatigue, expanding Healthcare Professional (HCP)/patient touchpoints, and growing stakeholder expectations for relevance. Traditional engagement strategies, characterized by fragmented data, siloed operational workflows, and legacy technology systems built for function-level enablement, have led to disjointed engagement and effort duplicity across enterprise teams. Systems of Execution (SoE) address this challenge by acting as an intelligent execution layer that unifies data across commercial, medical affairs, and patient services to activate cross-functional synergies in delivering coordinated stakeholder-centric omnichannel engagement across the enterprise. By leveraging real-time data signals, AI-powered next-best-action recommendations, and automated adaptive engagement workflows, SoE enable enterprises to autonomously deliver personalized and contextually relevant stakeholder interactions with minimal human intervention. This report outlines core SoE capabilities and provides life sciences CXOs with a clear implementation roadmap. It helps life sciences CXOs achieve personalized, enterprise-scale omnichannel execution, designed to surface cross-functional insights and autonomously act on them, to deliver coordinated omnichannel engagement across enterprise functions.
  • PEAK Matrix®

    June 09, 2025
    The life sciences industry is undergoing rapid digital transformation, fueled by the need for greater agility, regulatory compliance, and patient-centric operations. Enterprise platforms such as SAP, Oracle, and Salesforce have evolved from back-end systems of record to strategic innovation enablers, powering R&D, strengthening supply chains, and enhancing commercial effectiveness. However, challenges remain, as many organizations still operate fragmented legacy systems, struggle with complex migrations, and navigate the trade-offs between global standardization and local compliance. To address these needs, providers are investing in industry-specific accelerators, compliance-ready architectures, and intelligent automation capabilities. They are strengthening their expertise across SAP, Oracle, and Salesforce platforms, while also expanding AI/ML offerings to drive more proactive, insights-led operations. In this report, we assess 20 life sciences enterprise platform providers and position them on Everest Group’s PEAK Matrix®, a composite index of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performances against each other. Scope Industry: life sciences Geography: global Services: life sciences enterprise platform services Contents In this report, we examine: The provider landscape for life sciences enterprise platform services Life sciences enterprise platform providers on several capabilities and market success-related dimensions
  • PEAK Matrix®

    June 02, 2025
    Life sciences enterprises are embracing digital technologies to navigate the growing complexities in drug development, commercialization, and regulatory compliance. As economic pressures and competitive dynamics intensify, organizations are turning to digital services to improve operational resilience and achieve faster time-to-market. Providers are responding with targeted investments in AI / generative AI, data platforms, and industry-specific solutions to meet enterprise demands across the life sciences value chain. This PEAK Matrix® report offers a detailed evaluation of 35 providers delivering digital services in the life sciences sector, including biopharmaceutical, medical device, and others. It examines how these providers are enabling transformation through scalable solutions, co-innovation models, and differentiated capabilities. By assessing providers across dimensions such as market adoption, innovation, and delivery footprint, the report helps enterprise buyers identify the right strategic partners for their digital agendas. Scope Industry: life sciences (biopharmaceutical, medical devices, and others) Service: digital services Geography: global Contents In this report, we offer: Providers’ evaluations The evaluation scope Market trends Provider landscape analysis Key buyer considerations and takeaways Memberships Life Sciences Information Technology Sourcing and Vendor Management
  • State of the Market

    May 07, 2025
    The life sciences R&D engine is rapidly digitizing, and clinical development software now sits at its center. This report sizes the global clinical trials technology market at nearly US$6.5 billion for 2025 (8-10% CAGR) and dissects its four core segments – Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), Decentralized Clinical Trial (DCT) platforms, and clinical data and analytics suites. This study maps demand surges in oncology, rare disease, neurology, and obesity trials and examines the contrasting pressures of build-versus-buy debates and heightened data privacy scrutiny. Beyond market numbers, the report spotlights whitespaces such as end-to-end interoperability, real-time visualization, and true low/no-code configurability, analyzes segment-specific product trends (AI-driven EDC validation, next-generation CTMS forecasting, patient-centric DCT designs, and unified analytics hubs), and details the investment priorities sponsors and CROs are setting for 2025. A forward-looking section explores generative AI and agentic AI use cases, from autonomous protocol design to real-time safety monitoring, and outlines adoption stages and success prerequisites. These insights equip stakeholders to refine technology roadmaps, close capability gaps, and accelerate drug-development timelines. Scope Industry: life sciences Geography: global Contents In this report, we examine: 2023-25 clinical technology market size, growth, and segment mix Therapeutic area demand and shifting R&D spend Growth drivers and inhibitors Persistent gaps and sponsor-sourcing criteria Product-innovation themes across EDC, CTMS, DCT, and analytics High-potential generative AI and agentic AI applications and adoption stages 2025 investment priorities for sponsors, CROs, and technology providers
  • PEAK Matrix®

    April 03, 2025
    Pharmacovigilance (PV) has evolved into a strategic imperative, driven by intensified regulatory scrutiny and an increasing focus on patient safety. Pharmaceutical companies now face a rapidly evolving landscape characterized by rising adverse event volumes, fragmented real-world data sources, and increasingly complex global regulatory frameworks. Regional variations in drug safety reporting requirements further compound compliance challenges across diverse markets. At the same time, the demand for timely and accurate reporting has intensified, particularly as next-generation technologies introduce operational efficiencies while simultaneously raising regulatory concerns regarding the ethical and compliance implications of generative AI in PV. To navigate these complexities, external providers have become indispensable partners, offering deep PV expertise and adaptable support models. These providers bring proven drug safety process frameworks, highly trained PV professionals, and localized regulatory expertise, including qualified persons for PV, ensuring seamless compliance across global markets. Recognizing the need for enhanced efficiency, providers are investing in AI, automation, and advanced analytics to optimize case processing, adverse event management, and signal detection, all while reducing costs and improving operational scalability. In this report, we assess 29 PV operations providers featured on the Pharmacovigilance (PV) Operations PEAK Matrix®. Each provider profile provides a holistic picture of its service focus, solution offerings, and domain investments. The assessment is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading PV providers, client reference checks, and an ongoing analysis of the PV operations market. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading PV providers, client reference checks, and ongoing analysis of the PV market Contents This report analyzes 29 providers in detail and includes: Their relative positioning on Everest Group’s Pre-approval Pharmacovigilance (PV) Operations PEAK Matrix® Their relative positioning on Everest Group’s Post-approval Pharmacovigilance (PV) Operations PEAK Matrix® A comparison of their capabilities and market shares Their strengths and limitations
  • Webinar

    March 11, 2025
    Enterprise spending priorities in traditional areas have largely matured, and they have a playbook on how to optimize it. However, a wave of new pressures – including evolving regulations, geopolitical shifts, supply chain disruptions, tariffs, and rising customer experience (CX) expectations – is forcing executives to rethink how they can do more with less. With the rapid advancement and availability of new technologies, the question now is: What areas of enterprise spend remain untouched, and how can executives optimize these areas while delivering on the promise of AI and CX? What questions did the webinar answer? As an enterprise tech or operations leader, what new ways can I leverage my sourcing options that I haven’t done in the past? As a service or tech provider, what emerging spending opportunities can I pursue that were previously unavailable for outsourcing?
  • Provider Compendium

    Feb. 28, 2025
    Decentralized and hybrid designs add more complexity to clinical trials, generating vast data volumes from diverse sources. This complexity creates significant data management challenges. In response, sponsors are adopting unified clinical Data and Analytics (D&A) platforms to centralize and standardize clinical data for actionable insights, offering real-time monitoring, predictive analytics, and risk management. These platforms transform disparate datasets into cohesive, structured formats, helping stakeholders detect outliers, predict adverse events, and generate on-demand dashboards and reports. D&A platforms offer centralized repositories, Risk-based Quality Management (RBQM), and seamless integration with Electronic Health Records (EHRs), wearables, and medical devices. These features improve data access and interoperability, contributing to more informed decision-making and enhanced quality and risk oversight. To meet sponsor needs, clinical D&A platform providers are integrating AI and generative AI to automate repetitive tasks, generate insights, and strengthen quality and risk management. In this report, we analyze 18 clinical D&A platform providers’ capabilities and offerings. The report empowers buyers to select the right provider for their sourcing considerations and enables providers to benchmark themselves against their competition. Scope Industry: life sciences Geography: global Contents In this report, we: Examine the clinical D&A platform provider landscape Assess clinical D&A platform providers on their capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management
  • Provider Compendium

    Feb. 14, 2025
    Electronic Data Capture (EDC) systems are integral to clinical research, enabling clinical data collection, storage, and management. EDCs mark a significant shift from paper-based case report forms to digital and web-based trial data collection. The COVID-19 pandemic further emphasized EDC systems’ importance as the need for remote and decentralized clinical trials surged. The pandemic highlighted the need for robust, flexible, and secure data capture solutions to support treatments’ and vaccines’ rapid development and approval. These platforms have evolved to centralize data collection, improve data quality, and enable real-time clinical trial monitoring. They now integrate complex clinical data sources, such as electronic health records, laboratory data, clinical trial management systems, connected devices, and real-world data. Overall, EDC systems have significant benefits in clinical data collection, storage, and management. In this report, we assess 20 EDC product providers. The report enables buyers to choose the best-fit provider based on their sourcing considerations and empowers providers to benchmark themselves against their peers. Scope Industry: life sciences Geography: global Contents In this report, we: Examine the EDC product provider landscape Assess clinical EDC product providers on their capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management
  • Tech Launch Perspective

    Jan. 27, 2025
    Life sciences enterprises are increasingly focusing on Real-world Evidence / Real-world Data (RWE/RWD) to promote patient centricity, identify the next opportunity, and demonstrate value for their investments. Enterprises are seeking next-generation solutions to address interoperability and data access challenges. This shift compels providers to innovate their offerings and introduce advanced solutions that enhance analytics and insights, enable interoperability, and enhance data security. Following suit, Oracle has launched its Analytics Intelligence for Life Sciences offering, which provides AI-enabled workflows, enhanced data interoperability, and pre-integrated datasets. In this report, we examine Oracle’s current market position, key product announcements, and industry objectives. We also review Oracle’s RWE/RWD technology and cover essential RWE/RWD issues and objectives for life sciences enterprises.  Scope Industry: life sciences Geography: global Segment: RWE/RWD platforms Contents In this report, we examine: Key enterprise RWE/RWD issues and objectives Oracle’s Analytics Intelligence for Life Sciences announcement Memberships Life Sciences Information Technology Sourcing and Vendor Management
  • PEAK Matrix®

    Nov. 12, 2024
    Due to decentralized and hybrid designs, the growing clinical trial complexity generates vast data volumes from diverse sources and creates significant data management challenges. In response, sponsors are increasingly employing unified clinical data and analytics (D&A) platforms to centralize and standardize clinical data to gain actionable insights, offering real-time monitoring, predictive analytics, and risk management. These platforms transform disparate datasets into cohesive, structured formats, allowing stakeholders to detect outliers, predict adverse events, and generate on-demand dashboards and reports. D&A platforms offer centralized repositories, Risk-Based Quality Management (RBQM), and seamless integration with Electronic Health Records (EHRs), wearables, and medical devices. These features improve data access and interoperability, contributing to more informed decision-making and enhanced quality and risk oversight. Clinical D&A platform providers are incorporating cutting-edge AI and generative AI capabilities to automate repetitive tasks, generate insights, and strengthen quality and risk management to address sponsor needs. In this report, we analyze 18 clinical D&A platform providers featured on the Everest Group’s PEAK Matrix® based on their capabilities, offerings, and market impact. The report will empower buyers to choose the right provider for their sourcing considerations and enable providers to benchmark themselves against their competition. Scope Industry: life sciences Geography: global Contents In this report, we: Examine the provider landscape for clinical D&A platforms Assess clinical D&A platform providers on capabilities and market success-related dimensions Position the providers on Everest Group’s PEAK Matrix® framework as Leaders, Major Contenders, and Aspirants Compare providers’ key strengths and limitations Membership(s) Clinical Development Technology Sourcing and Vendor Management